María-José Escribá
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
María-José Escribá has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Laura Escrich
IVF Laboratory, Instituto Valenciano de Infertilidad (IVI Valencia), University of Valencia, Valencia, Spain
4 shared publicationsNoelia Grau
IVF Laboratory, Instituto Valenciano de Infertilidad (IVI Valencia), University of Valencia, Valencia, Spain
4 shared publicationsJosé Remohí
IVF Laboratory, University Institute IVI Valencia, Valencia, Spain; Department of Pediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain
2 shared publicationsYolanda Galiana
IVF Laboratory, Instituto Valenciano de Infertilidad (IVI Valencia), University of Valencia, Valencia, Spain
2 shared publicationsAmparo Mercader
Universitary Institute IVI Valencia
1 shared publication- Antonio Pellicer
Department of Paediatrics, Obstetrics and Gynecology, University of Valencia
1 shared publication
Latest Publications
- 1 May 2016
- Published by Elsevier in Fertility and Sterility
- Vol. 105 (5) , 1360-1368.e1
Kinetics of the early development of uniparental human haploid embryos
- 1 May 2016
- Published by Elsevier in Fertility and Sterility
- Vol. 105 (5) , 1360-1368.e1
Kinetics of the early development of uniparental human haploid embryos
- 1 September 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 104 (3) , 728-735
Morphokinetics as a predictor of self-correction to diploidy in tripronucleated intracytoplasmic sperm injection–derived human embryos
- 1 September 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 104 (3) , 728-735
Morphokinetics as a predictor of self-correction to diploidy in tripronucleated intracytoplasmic sperm injection–derived human embryos
- 3 July 2013
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 30 (8) , 1043-1047
Short-term storage of tripronucleated human embryos
To determine the survival and subsequent in vitro development of human cleavage stage embryos and hatched blastocysts following varying periods of short-term storage at 4 °C, using tripronucleated human embryos (TPN) as a model. TPN cleavage embryos and hatched blastocysts short-term stored at 4 °C for 0 h (control), 24 h and 48 h. The main outcome measures were: survival rates (SR) and in vitro developmental ability (blastocyst rate and blastocyst-re-expansion rate) in each of the groups after storage. Cleavage-stage TPN survived at comparable rates to controls, regardless of storage time (average: 97.3 %). The in vitro development of cleavage-stage TPN stored for 24 h was comparable to that of controls (average 64.7 %), but was significantly impaired when storage lasted 48-h (20.8 %). After artificial shrinkage, SR was comparable in 24-h-stored and non-stored hatched blastocysts (85.7 %; p > 0.05), but was significantly impaired in the 48-h-stored group (20.0 %). Following 24-h storage, the re-expansion rate of hatched blastocysts was similar to that of controls (average: 57.1 %; p > 0.05), but was higher than that of the 48-h-stored group (15.0 %; p TPN human cleavage embryos and blastocysts can be successfully stored short-term for up to 24 h at 4 °C without using cryoprotectants without any significant negative impact on survival or subsequent in vitro development.
- 3 July 2013
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 30 (8) , 1043-1047
Short-term storage of tripronucleated human embryos
To determine the survival and subsequent in vitro development of human cleavage stage embryos and hatched blastocysts following varying periods of short-term storage at 4 °C, using tripronucleated human embryos (TPN) as a model. TPN cleavage embryos and hatched blastocysts short-term stored at 4 °C for 0 h (control), 24 h and 48 h. The main outcome measures were: survival rates (SR) and in vitro developmental ability (blastocyst rate and blastocyst-re-expansion rate) in each of the groups after storage. Cleavage-stage TPN survived at comparable rates to controls, regardless of storage time (average: 97.3 %). The in vitro development of cleavage-stage TPN stored for 24 h was comparable to that of controls (average 64.7 %), but was significantly impaired when storage lasted 48-h (20.8 %). After artificial shrinkage, SR was comparable in 24-h-stored and non-stored hatched blastocysts (85.7 %; p > 0.05), but was significantly impaired in the 48-h-stored group (20.0 %). Following 24-h storage, the re-expansion rate of hatched blastocysts was similar to that of controls (average: 57.1 %; p > 0.05), but was higher than that of the 48-h-stored group (15.0 %; p TPN human cleavage embryos and blastocysts can be successfully stored short-term for up to 24 h at 4 °C without using cryoprotectants without any significant negative impact on survival or subsequent in vitro development.
- 11 September 2012
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 29 (11) , 1261-1265
Spontaneous in vitro maturation of oocytes prior to ovarian tissue cryopreservation in natural cycles of oncologic patients
To evaluate the recovery rate and spontaneous in vitro maturation (IVM) of immature oocytes enclosed within or released from follicles during the processing of ovarian tissue prior to its cryopreservation. Thirty-three oncologic patients who had not previously undergone chemo or radiotherapy underwent ovarian tissue cryopreservation (OTC) during natural menstrual cycles. Immature oocytes, enclosed within follicles or released during ovarian cortex processing, were collected and matured spontaneously in vitro for 48 h. Nuclear maturation was assessed every 24 h and the ability of the IVM oocytes to display a normal activation response following parthenogenetic activation was evaluated. The following outcome measures were also evaluated: disease, age, FSH, LH, E2, P4 and AMH serum levels, menstrual cycle day, recovery and spontaneous IVM and parthenogenetic activation rates. Oocytes recovered per patient were 3.3 ± 0.7 (1.8–4.7 oocytes, 95CI), regardless of the menstrual phase. The mean number of IVM oocytes per patient was 1.3 ± 0.2 oocytes (95CI: 0.8–1.8), regardless of menstrual phase (p = 0.86) and oocyte origin (p = 0.61). Forty-one percent of oocytes extruded the second polar body and formed one pronucleus after parthenogenetic activation. Twenty-one of the 33 women (63.6 %) requesting OTC produced at least one mature oocyte.
- 11 September 2012
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 29 (11) , 1261-1265
Spontaneous in vitro maturation of oocytes prior to ovarian tissue cryopreservation in natural cycles of oncologic patients
To evaluate the recovery rate and spontaneous in vitro maturation (IVM) of immature oocytes enclosed within or released from follicles during the processing of ovarian tissue prior to its cryopreservation. Thirty-three oncologic patients who had not previously undergone chemo or radiotherapy underwent ovarian tissue cryopreservation (OTC) during natural menstrual cycles. Immature oocytes, enclosed within follicles or released during ovarian cortex processing, were collected and matured spontaneously in vitro for 48 h. Nuclear maturation was assessed every 24 h and the ability of the IVM oocytes to display a normal activation response following parthenogenetic activation was evaluated. The following outcome measures were also evaluated: disease, age, FSH, LH, E2, P4 and AMH serum levels, menstrual cycle day, recovery and spontaneous IVM and parthenogenetic activation rates. Oocytes recovered per patient were 3.3 ± 0.7 (1.8–4.7 oocytes, 95CI), regardless of the menstrual phase. The mean number of IVM oocytes per patient was 1.3 ± 0.2 oocytes (95CI: 0.8–1.8), regardless of menstrual phase (p = 0.86) and oocyte origin (p = 0.61). Forty-one percent of oocytes extruded the second polar body and formed one pronucleus after parthenogenetic activation. Twenty-one of the 33 women (63.6 %) requesting OTC produced at least one mature oocyte.